Cambridge biotech Moderna is increasing its manufacturing capacity of the Covid-19 vaccine over the next two years: to 700 million doses in 2021, up from 600 million, and to 1.4 billion doses in 2022. The company is also exploring whether its coronavirus vaccine can be administered at a lower dose.